The case for & against
Bull & Bear analysis
Bearish
CRISPR Therapeutics AG (NASDAQ:CRSP) is a leading biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 technology. Positioned at the forefront of the gene-editing landscape, CRISPR Therapeutics' primary theme revolves around ongoing advancements in genetic therapies, with significant attention on its lead product candidate, Casgevy, which has received recent FDA approval for treating younger patients.
Bull says
- ↑FDA approval of Casgevy for sickle cell and β-thalassemia expands U.S. base by ~5,500 pediatric patients
- ↑Bank of America, HC Wainwright, Piper Sandler uphold buy ratings and $110 price target
- ↑$2.4 B in cash funds R&D and operations through 2026
- ↑Upward earnings revisions signal improving price momentum
- ↑Moderate liquidity and falling short interest could trigger a short squeeze rally
- ↑Strong patent portfolio and first-mover CRISPR edge bolster competitive moat
Bear says
- ↓Q2 2026 projected EPS of -$1.12 and revenue of $7.4 M indicate ongoing losses
- ↓Negative profitability metrics and weak earnings yield highlight return inefficiency
- ↓High volatility and significant short interest reflect bearish market sentiment
- ↓5.3% stock pullback post-approval shows vulnerability to sentiment swings
- ↓Emerging CRISPR rivals (EDIT, NTLA) heighten competitive pressure
- ↓Heavy cash burn and uncertain commercialization timelines raise financing risk
Investment themes with CRSP
Biotech↓ -3.20%
Genetic and drug innovations driving medical breakthroughs
APLS · RVMD · SMMT